ISIN | LU2814038423 |
---|---|
Valorennummer | 134918491 |
Bloomberg Global ID | |
Fondsname | DNB Fund-Biotechnology Institutional A EUR |
Fondsanbieter |
DNB Asset Management AS
Stockholm, Schweden Telefon: +46 8 473 41 00 Web: www.cim.se |
Fondsanbieter | DNB Asset Management AS |
Vertreter in der Schweiz |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(en) | |
Anlagekategorie | Andere Fonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | keine Ausgabekommission und/oder Gebühren zugunsten des Fonds (Ausgabe erfolgt zum Inventarwert) |
Konditionen bei der Rücknahme | Keine Rücknahmekommission und/oder Gebühren zugunsten des Fonds (Rücknahme erfolgt zum Inventarwert) |
Investment-Strategie *** | The Sub-Fund seeks to invest mainly in equities of companies operating in or associated with the biotechnology, diagnostics, pharmaceuticals, biomedicine, gene therapy and other health care related industries, with the aim to achieve a positive relative return over the long- term. Geographically the Sub-Fund has full flexibility. |
Besonderheiten |
Aktueller Preis * | 111.59 EUR | 20.02.2025 |
---|---|---|
Vorheriger Preis * | 110.64 EUR | 19.02.2025 |
52 Wochen Hoch * | 114.17 EUR | 05.02.2025 |
52 Wochen Tief * | 103.87 EUR | 03.10.2024 |
NAV * | 111.59 EUR | 20.02.2025 |
Ausgabepreis * | 111.59 EUR | 20.02.2025 |
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 5'638'301 | |
Anteilsklassevermögen *** | 1'119'720 | |
Trading Information SIX |
YTD-Performance | +3.96% |
31.12.2024 - 20.02.2025
31.12.2024 20.02.2025 |
---|---|---|
YTD-Performance (in CHF) | +4.30% |
31.12.2024 - 20.02.2025
31.12.2024 20.02.2025 |
1 Monat | +1.84% |
21.01.2025 - 20.02.2025
21.01.2025 20.02.2025 |
3 Monate | +4.93% |
20.11.2024 - 20.02.2025
20.11.2024 20.02.2025 |
6 Monate | +0.53% |
20.08.2024 - 20.02.2025
20.08.2024 20.02.2025 |
1 Jahr | +4.02% |
19.07.2024 - 20.02.2025
19.07.2024 20.02.2025 |
2 Jahre | - | - |
3 Jahre | - | - |
5 Jahre | - | - |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
argenx SE | 6.16% | |
---|---|---|
Biomarin Pharmaceutical Inc | 6.15% | |
Vertex Pharmaceuticals Inc | 4.65% | |
Amgen Inc | 4.49% | |
Neurocrine Biosciences Inc | 4.07% | |
Intra-Cellular Therapies Inc | 3.80% | |
Xenon Pharmaceuticals Inc | 3.26% | |
Regeneron Pharmaceuticals Inc | 3.02% | |
Exact Sciences Corp | 3.01% | |
Alnylam Pharmaceuticals Inc | 3.00% | |
Letzte Daten-Aktualisierung | 31.12.2024 |
TER *** | 0.77% |
---|---|
Datum TER *** | 30.06.2024 |
Performance Fee *** | 10.00% |
PTR | |
Max. Management Fee *** | 1.75% |
Ongoing Charges *** | 0.82% |
SRRI ***
|
|
Datum SRRI *** | 31.01.2025 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |